Longboard Pharmaceuticals Inc expected to post a loss of 69 cents a share - Earnings Preview

Longboard Pharmaceuticals

28/02/2023 21:48

* Longboard Pharmaceuticals Inc  LBPH.OQ   LBPH.O  is
expected
to show no change in quarterly revenue when it reports 
results on March 2. 
    * 
    * ​Refinitiv's mean analyst estimate for Longboard
Pharmaceuticals
Inc is for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $15.5​, above​ its last closing price
of $5.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.66       -0.64      -0.68     Missed  -6.9
 Jun. 30 2022  -0.60       -0.57      -0.67     Missed  -17
 Mar. 31 2022  -0.58       -0.55      -0.56     Missed  -1.3​
 Dec. 31 2021  -0.42       -0.43      -0.52     Missed  -20.5
 ​​Sep.        -0.47       -0.48      -0.38     Beat    20.1
 30 2021                                                
 Jun. 30 2021  -0.67       -0.67      -0.41     Beat    39.1​
 Mar. 31 2021  -0.94       -0.94      -0.84     Beat    10.6
 This summary was machine generated February 28 at 21:48 GMT. 
All figures in US dollars  unless otherwise stated